Gil Bianco is Independent Director of the Company. He has served on our board of directors since April 2010. From November 2009 to November 2012, Mr. Bianco served as a director of D-Pharm Ltd., an Israeli public biopharmaceutical company, and from May 2007 to May 2010, Mr. Bianco served as a director of BioLineRx Ltd. (Nasdaq: BLRX), a clinical-stage biopharmaceutical development company. From December 2003 to December 2009, Mr. Bianco served as an external director of the Tel Aviv Stock Exchange Ltd. Prior to that, from 2001 to 2003, Mr. Bianco served as chief executive officer of Agis Industries Ltd., a pharmaceutical manufacturer. Mr. Bianco previously served as an external director at Mazor Robotics Ltd. (Nasdaq: MZOR), a medical device company, from November 2007 until its acquisition in 2018. Mr. Bianco is also a director of several private companies in the fields of biotech and medical devices. Mr. Bianco holds a B.A. in economics and accounting from Tel-Aviv University in Tel-Aviv, Israel and is a certified public accountant in Israel.
Gil Bianco is 67, he's been the Independent Director of Intec Parent Inc since 2010. There are 1 older and 6 younger executives at Intec Parent Inc. The oldest executive at Intec Parent Inc is John Kozarich, 70, who is the Chairman of the Board.
Gil's mailing address filed with the SEC is C/O INTEC PHARMA LTD., 12 HARTOM STREET, JERUSALEM, L3, 9777512.
Over the last 6 years, insiders at Intec Parent Inc have traded over $284,445 worth of Intec Parent Inc stock and bought 245,000 units worth $117,350 . The most active insiders traders include Pharma Technologies Ltd.Ore..., Roger Pomerantz, and Jeffrey A Meckler. On average, Intec Parent Inc executives and independent directors trade stock every 27 days with the average trade being worth of $1,864,936. The most recent stock trade was executed by Pharma Technologies Ltd.Ore... on 31 January 2020, trading 915,951 units of NTEC stock currently worth $283,945.
Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism.
Intec Parent Inc executives and other stock owners filed with the SEC include: